MRC1 and neoplasm: After treatment, the TIME tended to be similar between tumor implantation sites (Figures 3C, D), with a significant down-regulation of B cells and an upregulation of F4/80+CD206+MHC-II+ cells in both SC and orthotopic sensitive MC38 tumors exposed to anti-PD1 antibody (p<0,0001, Figures 3E, F).